GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive Variables in Indian School Children
Not Applicable
Completed
- Conditions
- Cognition
- Interventions
- Dietary Supplement: Beverage powder fortified with micronutrients and Bacopa monnieri extractOther: Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 310
- Registration Number
- NCT02416245
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Device: SERETIDE MDIDevice: Placebo DISKUS InhalerDevice: Placebo MDI
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 111
- Registration Number
- NCT02416180
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Tolerability Assessment Study of Three Wash Products in Infants
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Test shampooOther: Test bath foamOther: Test head to toe wash
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT02403999
- Locations
- 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom
Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
Phase 4
Withdrawn
- Conditions
- Skin Irritation
- Interventions
- Other: SalineDrug: Topical SprayDrug: Topical Gel
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02400320
Evaluation of Oral Hygiene Products in an In Situ Caries Model
Not Applicable
Completed
- Conditions
- Dental Caries
- Interventions
- Drug: Fluoride free toothpasteDrug: Fluoride toothpasteDrug: Fluoride mouthwash
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT02399163
- Locations
- 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States
Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays
Phase 4
Completed
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- Drug: MF nasal sprayDrug: FF nasal spray
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT02397915
- Locations
- 🇷🇺
GSK Investigational Site, Stavropol, Russian Federation
A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT02386436
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
Phase 1
Withdrawn
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02380313
Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women
Phase 1
Completed
- Conditions
- Obstetric Labour, Premature
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT02377414
- Locations
- 🇺🇸
GSK Investigational Site, Glendale, California, United States
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
Phase 4
Completed
- Conditions
- Diphtheria-Tetanus-acellular Pertussis Vaccines
- Interventions
- Biological: Boostrix™Drug: Saline placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 688
- Registration Number
- NCT02377349
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
© Copyright 2025. All Rights Reserved by MedPath